| Human immunodeficiency virus I infection
Apretude vs Tivicay
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Apretude vs Tivicay with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTivicay has a higher rate of injection site reactions vs Apretude based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tivicay but not Apretude, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Apretude
Tivicay
At A Glance
IM injection
Every 2 months
HIV integrase strand transfer inhibitor
Oral
Once daily (or twice daily with certain inducers)
Integrase strand transfer inhibitor (INSTI)
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 600-mg (3-mL) gluteal IM initiation injections 1 month apart for 2 consecutive months, then 600-mg (3-mL) every 2 months; optional oral lead-in with cabotegravir 30 mg once daily for at least 28 days prior to first injection.
Human immunodeficiency virus I infection (treatment-naive or INSTI-naive adults) 50 mg orally once daily, with or without food. Adjust to 50 mg twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (INSTI-experienced adults with resistance) 50 mg orally twice daily, with or without food, combined with optimized background therapy.
Human immunodeficiency virus I infection (pediatric patients 3 kg to <6 kg) TIVICAY PD 5 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 6 kg to <10 kg) TIVICAY PD 15 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 10 kg to <14 kg) TIVICAY PD 20 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 14 kg to <20 kg) TIVICAY PD 25 mg orally once daily or TIVICAY tablets 40 mg once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients >=20 kg) TIVICAY PD 30 mg orally once daily or TIVICAY tablets 50 mg once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (virologically suppressed adults switching to dual therapy) 50 mg orally once daily in combination with rilpivirine 25 mg once daily, with or without food.
Contraindications
- Unknown or positive HIV-1 status
- Previous hypersensitivity reaction to cabotegravir
- Coadministration with anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin) due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
- Coadministration with antimycobacterials rifampin or rifapentine due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
- Hypersensitivity to dolutegravir
- Coadministration with dofetilide
Adverse Reactions
Most common (>=1%) Injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, upper respiratory tract infection
Serious Hypersensitivity reactions, hepatotoxicity, depressive disorders including depression, suicidal ideation, and suicide attempt
Postmarketing Hypersensitivity reactions (angioedema, urticaria), Stevens-Johnson syndrome/toxic epidermal necrolysis
Most common (>=2%, treatment-naive) Insomnia, headache, diarrhea, nausea, fatigue, rash
Serious Hypersensitivity reactions, hepatotoxicity, immune reconstitution syndrome
Postmarketing Sideroblastic anemia, acute liver failure, weight increased, arthralgia, myalgia, anxiety
Pharmacology
Cabotegravir is an HIV integrase strand transfer inhibitor (INSTI) that inhibits HIV replication by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for the HIV replication cycle.
Dolutegravir is an HIV-1 integrase strand transfer inhibitor that blocks the strand transfer step of retroviral DNA integration essential for HIV replication by binding to the integrase active site.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Apretude
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Tivicay
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Apretude
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tivicay
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Apretude
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Tivicay
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Apretude Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ApretudeView full Apretude profile
TivicayView full Tivicay profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.